ES2309374T3 - Combinacion sinergica que comprende reflumilast y r,r-formoterol. - Google Patents
Combinacion sinergica que comprende reflumilast y r,r-formoterol. Download PDFInfo
- Publication number
- ES2309374T3 ES2309374T3 ES03780056T ES03780056T ES2309374T3 ES 2309374 T3 ES2309374 T3 ES 2309374T3 ES 03780056 T ES03780056 T ES 03780056T ES 03780056 T ES03780056 T ES 03780056T ES 2309374 T3 ES2309374 T3 ES 2309374T3
- Authority
- ES
- Spain
- Prior art keywords
- formoterol
- roflumilast
- administered
- medication
- pharmacologically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960002848 formoterol Drugs 0.000 title description 3
- 230000002195 synergetic effect Effects 0.000 title description 3
- BPZSYCZIITTYBL-YJYMSZOUSA-N R-Formoterol Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-YJYMSZOUSA-N 0.000 claims abstract description 35
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960002586 roflumilast Drugs 0.000 claims abstract description 29
- 208000018569 Respiratory Tract disease Diseases 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 25
- 229940079593 drug Drugs 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000006673 asthma Diseases 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 210000002345 respiratory system Anatomy 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 206010052613 Allergic bronchitis Diseases 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- PCGSQNPMMSALEJ-UHFFFAOYSA-N roflumilast n-oxide Chemical compound ClC1=C[N+]([O-])=CC(Cl)=C1NC(=O)C1=CC=C(OC(F)F)C(OCC2CC2)=C1 PCGSQNPMMSALEJ-UHFFFAOYSA-N 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims 4
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 17
- 239000002253 acid Substances 0.000 description 9
- 208000019693 Lung disease Diseases 0.000 description 8
- 239000000443 aerosol Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 4
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 4
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- -1 for example Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- ZLOIAYYVSZYHIF-UHFFFAOYSA-N C(CCC)(=O)O.OC1=CC=C(C(=O)C2=C(C(=O)O)C=CC=C2)C=C1 Chemical compound C(CCC)(=O)O.OC1=CC=C(C(=O)C2=C(C(=O)O)C=CC=C2)C=C1 ZLOIAYYVSZYHIF-UHFFFAOYSA-N 0.000 description 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 150000001440 androstane derivatives Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003580 lung surfactant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000007519 polyprotic acids Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02026504 | 2002-11-27 | ||
| EP02026504 | 2002-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2309374T3 true ES2309374T3 (es) | 2008-12-16 |
Family
ID=32338001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03780056T Expired - Lifetime ES2309374T3 (es) | 2002-11-27 | 2003-11-26 | Combinacion sinergica que comprende reflumilast y r,r-formoterol. |
Country Status (31)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| ME00524B (me) | 2003-03-10 | 2011-10-10 | Astrazeneca Ab | Novi postupak za dobijanje roflumilasta |
| EP1861074B1 (en) | 2005-03-16 | 2013-04-24 | Takeda GmbH | Taste masked dosage form containing roflumilast |
| WO2013077830A1 (en) * | 2011-11-25 | 2013-05-30 | Mahmut Bilgic | Synergistilly active combinations of roflumilast and carmoterol |
| CN103784443A (zh) * | 2014-02-18 | 2014-05-14 | 青岛市城阳区人民医院 | 一种包含沙美特罗和罗氟司特的药物组合产品 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| EP0938467B1 (en) * | 1996-11-11 | 2002-06-12 | Sepracor, Inc. | Process for the preparation of optically pure isomers of formoterol |
| EA001758B1 (ru) * | 1997-02-17 | 2001-08-27 | Бык Гульден Ломберг Хемише Фабрик Гмбх | Композиции для лечения респираторного дистресс-синдрома взрослых или респираторного дистресс-синдрома новорожденных, содержащие 3-(циклопропилметокси)-n-(3,5-дихлор-4-пиридинил)-4-(дифторметокси)бензамид и легочное поверхностно-активное вещество |
| US6333354B1 (en) * | 1997-02-28 | 2001-12-25 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists |
| US6624181B1 (en) * | 1997-02-28 | 2003-09-23 | Altana Pharma Ag | Synergistic combination |
| BR9913152A (pt) * | 1998-08-26 | 2001-05-15 | Smithkline Beecham Corp | Terapias para tratamento de doenças pulmonares |
| US6303145B2 (en) * | 1999-05-10 | 2001-10-16 | Sepracor Inc. | (S,R) formoterol methods and compositions |
| EP1671651B1 (en) * | 1999-08-21 | 2009-11-11 | Nycomed GmbH | Synergistic combination of pumafentrine and salmeterol |
| GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| ATE381537T1 (de) * | 2001-03-22 | 2008-01-15 | Glaxo Group Ltd | Formanilid-derivative als beta2-adrenorezeptor- agonisten |
| ES2314052T3 (es) * | 2001-04-30 | 2009-03-16 | Glaxo Group Limited | Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa. |
-
2003
- 2003-11-26 US US10/535,817 patent/US20060199865A1/en not_active Abandoned
- 2003-11-26 DE DE60321954T patent/DE60321954D1/de not_active Expired - Lifetime
- 2003-11-26 CN CNA2003801036335A patent/CN1713902A/zh active Pending
- 2003-11-26 UA UAA200505965A patent/UA83017C2/uk unknown
- 2003-11-26 ME MEP-2008-781A patent/ME00488B/me unknown
- 2003-11-26 HR HRP20050580AA patent/HRP20050580B1/hr not_active IP Right Cessation
- 2003-11-26 RS YUP-2005/0383A patent/RS51082B/sr unknown
- 2003-11-26 SI SI200331345T patent/SI1567140T1/sl unknown
- 2003-11-26 PL PL375632A patent/PL214869B1/pl unknown
- 2003-11-26 NZ NZ540658A patent/NZ540658A/en not_active IP Right Cessation
- 2003-11-26 DK DK03780056T patent/DK1567140T3/da active
- 2003-11-26 AT AT03780056T patent/ATE399544T1/de active
- 2003-11-26 ES ES03780056T patent/ES2309374T3/es not_active Expired - Lifetime
- 2003-11-26 PT PT03780056T patent/PT1567140E/pt unknown
- 2003-11-26 MX MXPA05005438A patent/MXPA05005438A/es active IP Right Grant
- 2003-11-26 EP EP03780056A patent/EP1567140B1/en not_active Expired - Lifetime
- 2003-11-26 EA EA200500865A patent/EA009990B1/ru not_active IP Right Cessation
- 2003-11-26 AU AU2003288169A patent/AU2003288169B8/en not_active Ceased
- 2003-11-26 WO PCT/EP2003/013266 patent/WO2004047828A1/en not_active Ceased
- 2003-11-26 KR KR1020057009176A patent/KR20050094810A/ko not_active Ceased
- 2003-11-26 JP JP2004554476A patent/JP2006508993A/ja active Pending
- 2003-11-26 CA CA2506956A patent/CA2506956C/en not_active Expired - Fee Related
- 2003-11-26 BR BR0316475-6A patent/BR0316475A/pt not_active IP Right Cessation
-
2005
- 2005-04-25 ZA ZA200503307A patent/ZA200503307B/en unknown
- 2005-05-01 IL IL168307A patent/IL168307A/en not_active IP Right Cessation
- 2005-05-10 TN TNP2005000130A patent/TNSN05130A1/en unknown
- 2005-06-16 MA MA28342A patent/MA27538A1/fr unknown
- 2005-06-20 IS IS7899A patent/IS2576B/is unknown
- 2005-06-20 NO NO20053023A patent/NO334148B1/no not_active IP Right Cessation
- 2005-06-27 CO CO05062790A patent/CO5690571A2/es not_active Application Discontinuation
-
2008
- 2008-09-17 CY CY20081101016T patent/CY1110368T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2284531T3 (es) | Tratamiento nasal topico usando desloratadina y furoato de mometasona. | |
| FI2265257T4 (fi) | Aklidiniumia käsittävä inhalaatiokoostumus kroonisen keuhkoahtaumataudin hoitamiseksi | |
| HU226527B1 (hu) | Készítmények nátha kezelésére | |
| ES2300755T3 (es) | Combinacion sinergica que comprende roflumilast y un agente anticolinergico seleccionado de sales de tiotropio para el tratamiento de enfermedades respiratorias. | |
| ES2309357T3 (es) | Nueva combinacion sinergica que comprende roflumilast y formoterol. | |
| ES2309374T3 (es) | Combinacion sinergica que comprende reflumilast y r,r-formoterol. | |
| ES2201039T3 (es) | Combinacion de farmacos para el tratamiento del dolor de cabeza que comprende un farmaco anti-inflamatorio no esteroideo. | |
| KR20130140672A (ko) | 기침 치료용 카보네이트 유도체 | |
| HK1081862B (en) | Synergistic combination comprising roflumilast and (r,r)-formoterol | |
| HK1081861B (en) | New synergistic combination comprising roflumilast and formoterol | |
| JP2004529893A5 (cg-RX-API-DMAC7.html) | ||
| NZ707754B2 (en) | Combination of glycopyrrolate and a beta2 -agonist | |
| TW201605440A (zh) | 阿地銨之新用途 |